Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Arturo Medina-Ruiz"'
Autor:
Arturo, Medina-Ruiz
Publikováno v:
Boletin de la Asociacion Medica de Puerto Rico. 103(4)
The atherosclerotic process begins in childhood and advances rapidly triggered by multiple genetic and environmental factors, including obesity. Obesity has reach epidemic proportions mainly by the consumption of junk food and a sedentary lifestyle.
Autor:
José, Pérez-Cardona, Víctor, Salgado, Arturo, Medina-Ruiz, José, Quilinchini, Alberto, Maldonado
Publikováno v:
Puerto Rico health sciences journal. 27(4)
A 45 year old man, intravenous drug user, without history of systemic illness, presented with fever, chills and an anterior left thorax pulsatile mass. Echocardiogram showed an anterior mediastinal fluid collection with no apparent pericardial commun
Autor:
Arturo, Medina-Ruiz
Publikováno v:
Puerto Rico health sciences journal. 27(4)
This article summarizes the principal publications and those evidence-based clinical trials on dyslipidemias, including their main findings and recommendations for practicing cardiologists and clinicians. Emphasis is given to the confirmed data regar
Publikováno v:
Boletin de la Asociacion Medica de Puerto Rico. 97(4)
Physicians are frequently concerned with the management of the surgical risk in patients with heart disease requiring non cardiac surgery. A preoperative evaluation helps to assess the cardiac risk for the planned surgery and helps to take measures t
Publikováno v:
Puerto Rico health sciences journal. 23(4)
Peripheral arterial disease results from the atherosclerotic involvement of arteries of the upper and lower extremities as well as that of the renal and carotid arteries. In view of the importance of its early recognition we have summarized the clini
Autor:
Arturo Medina-Ruiz, Juan F. Feliu
Publikováno v:
Drugs. 39
The efficacy and safety of enalapril and its effects on the quality of life were evaluated in 1017 Puerto Rican patients with uncomplicated mild to moderate essential hypertension. Enalapril was administered for 4 weeks in an open label, noncomparati